{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:08:56Z","timestamp":1753355336098,"version":"3.40.4"},"reference-count":46,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":582,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1111\/bjh.12731","type":"journal-article","created":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T12:00:54Z","timestamp":1390824054000},"page":"78-88","source":"Crossref","is-referenced-by-count":5,"title":["The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells<i>in vitro<\/i>, as a single agent and in combination with other drugs"],"prefix":"10.1111","volume":"165","author":[{"given":"Aneel","family":"Paulus","sequence":"first","affiliation":[{"name":"Department of Cancer Biology; Mayo Clinic; Jacksonville FL USA"},{"name":"Division of Hematology and Oncology; Mayo Clinic; Jacksonville FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisha","family":"Masood","sequence":"additional","affiliation":[{"name":"Department of Medicine; Roswell Park Cancer Institute; Buffalo NY USA"},{"name":"Department of Internal Medicine; State University of New York at Stony Brook University; Stony Brook NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kena C.","family":"Miller","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology; Mayo Clinic; Jacksonville FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. N. M.","family":"Nazmul H. Khan","sequence":"additional","affiliation":[{"name":"Department of Medicine; Roswell Park Cancer Institute; Buffalo NY USA"},{"name":"Department of Infectious Diseases; Roswell Park Cancer Institute; Buffalo NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drusilla","family":"Akhtar","sequence":"additional","affiliation":[{"name":"Department of Medicine; Roswell Park Cancer Institute; Buffalo NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Advani","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology; Mayo Clinic; Jacksonville FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Foran","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology; Mayo Clinic; Jacksonville FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candido","family":"Rivera","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology; Mayo Clinic; Jacksonville FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology; Mayo Clinic; Jacksonville FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Colon-Otero","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology; Mayo Clinic; Jacksonville FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasyapa","family":"Chitta","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology; Mayo Clinic; Jacksonville FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asher","family":"Chanan-Khan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology; Mayo Clinic; Jacksonville FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,1,27]]},"reference":[{"key":"10.1111\/bjh.12731-BIB0001|bjh12731-cit-0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","article-title":"The proteasome: structure, function, and role in the cell","volume":"29","author":"Adams","year":"2003","journal-title":"Cancer Treatment Reviews"},{"key":"10.1111\/bjh.12731-BIB0002|bjh12731-cit-0002","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1517\/17425255.2011.579105","article-title":"Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia","volume":"7","author":"Advani","year":"2011","journal-title":"Expert Opinion on Drug Metabolism and Toxicology"},{"key":"10.1111\/bjh.12731-BIB0003|bjh12731-cit-0003","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"10.1111\/bjh.12731-BIB0004|bjh12731-cit-0004","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2141.2011.08882.x","article-title":"Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response","volume":"155","author":"Chanan-Khan","year":"2011","journal-title":"British Journal of Haematology"},{"key":"10.1111\/bjh.12731-BIB0005|bjh12731-cit-0005","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells","volume":"17","author":"Chauhan","year":"2011","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/bjh.12731-BIB0006|bjh12731-cit-0006","first-page":"2861","article-title":"At-101 induces apoptosis waldenstrom macroglobulinemia cells resistant to bortezomib","volume":"114","author":"Chitta","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1111\/bjh.12731-BIB0007|bjh12731-cit-0007","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2011.37.0981","article-title":"Targeting the B-cell lymphoma\/leukemia 2 family in cancer","volume":"30","author":"Davids","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.12731-BIB0008|bjh12731-cit-0008","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1365-2141.2007.06856.x","article-title":"Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology","volume":"139","author":"Dores","year":"2007","journal-title":"British Journal of Haematology"},{"key":"10.1111\/bjh.12731-BIB0009|bjh12731-cit-0009","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1600-0609.2004.00406.x","article-title":"In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells","volume":"74","author":"Duechler","year":"2005","journal-title":"European Journal of Haematology"},{"key":"10.1111\/bjh.12731-BIB0010|bjh12731-cit-0010","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/cncr.22097","article-title":"Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia","volume":"107","author":"Faderl","year":"2006","journal-title":"Cancer"},{"key":"10.1111\/bjh.12731-BIB0011|bjh12731-cit-0011","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.onc.1210744","article-title":"BCL-2 family regulation by the 20S proteasome inhibitor bortezomib","volume":"27","author":"Fennell","year":"2008","journal-title":"Oncogene"},{"key":"10.1111\/bjh.12731-BIB0012|bjh12731-cit-0012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.mce.2008.10.001","article-title":"Molecular mechanisms regulating glucocorticoid sensitivity and resistance","volume":"300","author":"Gross","year":"2009","journal-title":"Molecular and Cellular Endocrinology"},{"issue":"Suppl 7","key":"10.1111\/bjh.12731-BIB0013|bjh12731-cit-0013","doi-asserted-by":"crossref","first-page":"vii154","DOI":"10.1093\/annonc\/mdq373","article-title":"Chronic lymphocytic leukemia","volume":"21","author":"Hallek","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1111\/bjh.12731-BIB0014|bjh12731-cit-0014","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a therapeutic target in multiple myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"10.1111\/bjh.12731-BIB0015|bjh12731-cit-0015","doi-asserted-by":"crossref","first-page":"16617","DOI":"10.1016\/S0021-9258(17)46267-3","article-title":"Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity","volume":"265","author":"Huang","year":"1990","journal-title":"Journal of Biological Chemistry"},{"key":"10.1111\/bjh.12731-BIB0016|bjh12731-cit-0016","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/sj.leu.2404483","article-title":"Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells","volume":"21","author":"Iglesias-Serret","year":"2007","journal-title":"Leukemia"},{"key":"10.1111\/bjh.12731-BIB0017|bjh12731-cit-0017","first-page":"6605","article-title":"AT-101, a small molecule Bcl-2 antagonist, in treatment naive CLL patients (pts) with high risk features; Preliminary results from an ongoing phase I trial","volume":"24","author":"James","year":"2006","journal-title":"Journal of Clinical Oncology (ASCO Meeting Abstracts)"},{"key":"10.1111\/bjh.12731-BIB0018|bjh12731-cit-0018","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.exphem.2008.01.003","article-title":"R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells","volume":"36","author":"Kline","year":"2008","journal-title":"Experimental Hematology"},{"key":"10.1111\/bjh.12731-BIB0019|bjh12731-cit-0019","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-07-1919","article-title":"Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)","volume":"68","author":"Konopleva","year":"2008","journal-title":"Cancer Research"},{"key":"10.1111\/bjh.12731-BIB0020|bjh12731-cit-0020","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Research"},{"key":"10.1111\/bjh.12731-BIB0021|bjh12731-cit-0021","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1158\/0008-5472.CAN-04-3684","article-title":"Mitochondrial-mediated disregulation of Ca2\u00a0+\u00a0 is a critical determinant of Velcade (PS-341\/bortezomib) cytotoxicity in myeloma cell lines","volume":"65","author":"Landowski","year":"2005","journal-title":"Cancer Research"},{"key":"10.1111\/bjh.12731-BIB0022|bjh12731-cit-0022","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1182\/blood-2008-04-150227","article-title":"Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib","volume":"112","author":"Liu","year":"2008","journal-title":"Blood"},{"key":"10.1111\/bjh.12731-BIB0023|bjh12731-cit-0023","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2141.2011.08984.x","article-title":"Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner","volume":"157","author":"Masood","year":"2011","journal-title":"British Journal of Haematology"},{"key":"10.1111\/bjh.12731-BIB0024|bjh12731-cit-0024","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1038\/cddis.2012.102","article-title":"Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim\/Bcl-2 complexes to activate Bax and Bak","volume":"3","author":"Melarangi","year":"2012","journal-title":"Cell Death and Disease"},{"key":"10.1111\/bjh.12731-BIB0025|bjh12731-cit-0025","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1158\/1078-0432.CCR-05-0308","article-title":"The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide","volume":"12","author":"O'Connor","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/bjh.12731-BIB0026|bjh12731-cit-0026","first-page":"4570","article-title":"Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia","volume":"9","author":"Pahler","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/bjh.12731-BIB0027|bjh12731-cit-0027","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0026-895X(25)09779-2","article-title":"Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase","volume":"34","author":"Parker","year":"1988","journal-title":"Molecular Pharmacology"},{"key":"10.1111\/bjh.12731-BIB0028|bjh12731-cit-0028","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/sj.leu.2403109","article-title":"The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells","volume":"17","author":"Pei","year":"2003","journal-title":"Leukemia"},{"key":"10.1111\/bjh.12731-BIB0029|bjh12731-cit-0029","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"Perez-Galan","year":"2006","journal-title":"Blood"},{"key":"10.1111\/bjh.12731-BIB0030|bjh12731-cit-0030","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2006-07-034173","article-title":"The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak","volume":"109","author":"Perez-Galan","year":"2007","journal-title":"Blood"},{"key":"10.1111\/bjh.12731-BIB0031|bjh12731-cit-0031","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/leu.2008.175","article-title":"BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its enhanced interaction with bortezomib in chronic lymphocytic leukemia cells","volume":"22","author":"Perez-Galan","year":"2008","journal-title":"Leukemia"},{"key":"10.1111\/bjh.12731-BIB0032|bjh12731-cit-0032","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0163-7258(91)90057-S","article-title":"Metabolism and action of purine nucleoside analogs","volume":"49","author":"Plunkett","year":"1991","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1111\/bjh.12731-BIB0033|bjh12731-cit-0033","first-page":"2","article-title":"Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies","volume":"20","author":"Plunkett","year":"1993","journal-title":"Seminars in Oncology"},{"key":"10.1111\/bjh.12731-BIB0034|bjh12731-cit-0034","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1111\/bjh.12731-BIB0035|bjh12731-cit-0035","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.12731-BIB0036|bjh12731-cit-0036","first-page":"9","article-title":"Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies","volume":"34","author":"Reed","year":"1997","journal-title":"Seminars in Hematology"},{"key":"10.1111\/bjh.12731-BIB0037|bjh12731-cit-0037","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/sonc.2002.30155","article-title":"Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers","volume":"29","author":"Reed","year":"2002","journal-title":"Seminars in Oncology"},{"key":"10.1111\/bjh.12731-BIB0038|bjh12731-cit-0038","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood.V81.1.143.143","article-title":"Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine","volume":"81","author":"Robertson","year":"1993","journal-title":"Blood"},{"key":"10.1111\/bjh.12731-BIB0039|bjh12731-cit-0039","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2165\/00003495-199345050-00009","article-title":"Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy","volume":"45","author":"Ross","year":"1993","journal-title":"Drugs"},{"key":"10.1111\/bjh.12731-BIB0040|bjh12731-cit-0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/10428199309086993","article-title":"The role of Bcl-2 in the pathogenesis of B chronic lymphocytic leukemia","volume":"11","author":"Schena","year":"1993","journal-title":"Leukaemia & Lymphoma"},{"key":"10.1111\/bjh.12731-BIB0041|bjh12731-cit-0041","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0006-2952(86)90521-6","article-title":"Incorporation of 9-beta-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA","volume":"35","author":"Spriggs","year":"1986","journal-title":"Biochemical Pharmacology"},{"key":"10.1111\/bjh.12731-BIB0042|bjh12731-cit-0042","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1750-2187-7-12","article-title":"Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine","volume":"7","author":"Stamelos","year":"2012","journal-title":"Journal of Molecular Signaling"},{"key":"10.1111\/bjh.12731-BIB0043|bjh12731-cit-0043","first-page":"1055","article-title":"Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2\/bax proteins in drug resistance","volume":"12","author":"Thomas","year":"1996","journal-title":"Oncogene"},{"key":"10.1111\/bjh.12731-BIB0044|bjh12731-cit-0044","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Research"},{"key":"10.1111\/bjh.12731-BIB0045|bjh12731-cit-0045","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2008-07-171231","article-title":"Why is CLL refractory to bortezomib?","volume":"112","author":"Wickremasinghe","year":"2008","journal-title":"Blood"},{"key":"10.1111\/bjh.12731-BIB0046|bjh12731-cit-0046","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3816\/CLML.2010.n.070","article-title":"Chronic lymphocytic leukemia: new concepts for future therapy","volume":"10","author":"Wierda","year":"2010","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12731","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjh.12731\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T17:34:04Z","timestamp":1746120844000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,27]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,4]]}},"URL":"https:\/\/doi.org\/10.1111\/bjh.12731","relation":{},"ISSN":["0007-1048"],"issn-type":[{"type":"print","value":"0007-1048"}],"subject":[],"published":{"date-parts":[[2014,1,27]]}}}